Please assess the completion status of the following clinical trial:

Trial Title: BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 70 years and older~* No treatment with any other investigational agent within 28 days or 2 half-lives (whichever is longer) prior to enrollment~Exclusion Criteria:~* Contraindications, warnings, and precautions for bevacizumab

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elderly Participants with Ovarian Cancer (Type: None): Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).